CN101501694B - 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 - Google Patents

用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 Download PDF

Info

Publication number
CN101501694B
CN101501694B CN2007800290322A CN200780029032A CN101501694B CN 101501694 B CN101501694 B CN 101501694B CN 2007800290322 A CN2007800290322 A CN 2007800290322A CN 200780029032 A CN200780029032 A CN 200780029032A CN 101501694 B CN101501694 B CN 101501694B
Authority
CN
China
Prior art keywords
protein
amino acid
peptide
residue
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800290322A
Other languages
English (en)
Chinese (zh)
Other versions
CN101501694A (zh
Inventor
卡伊·J·科尔霍夫
赫苏斯·苏尔多
米凯莱·文德鲁斯科洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Original Assignee
Lonza Biologics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics PLC filed Critical Lonza Biologics PLC
Publication of CN101501694A publication Critical patent/CN101501694A/zh
Application granted granted Critical
Publication of CN101501694B publication Critical patent/CN101501694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
CN2007800290322A 2006-08-04 2007-07-24 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 Expired - Fee Related CN101501694B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
US60/821,553 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
CN101501694A CN101501694A (zh) 2009-08-05
CN101501694B true CN101501694B (zh) 2011-11-30

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800290322A Expired - Fee Related CN101501694B (zh) 2006-08-04 2007-07-24 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法

Country Status (11)

Country Link
US (1) US8290713B2 (enExample)
EP (1) EP2047393A1 (enExample)
JP (1) JP2009545756A (enExample)
KR (1) KR20090047470A (enExample)
CN (1) CN101501694B (enExample)
AU (1) AU2007280282B2 (enExample)
CA (1) CA2657847A1 (enExample)
EA (1) EA016884B1 (enExample)
IL (1) IL196551A (enExample)
SG (1) SG173405A1 (enExample)
WO (1) WO2008015384A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108780098A (zh) * 2016-01-06 2018-11-09 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
EP2278998A1 (en) 2008-04-17 2011-02-02 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
WO2011047442A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
SG11201705275VA (en) * 2015-01-06 2017-07-28 Univ North Carolina State Modeling ribosome dynamics to optimize heterologous protein production
BR112018014870A2 (pt) * 2016-01-21 2018-12-11 Protein Dynamic Solutions Llc método e sistema para análise de dados espectrais
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004739B1 (ru) * 1999-11-05 2004-08-26 Эксоникс, Инк. ПЕПТИДНЫЕ АНАЛОГИ И МИМЕТИКИ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ IN VIVO ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНОМАЛЬНОЙ УКЛАДКОЙ БЕЛКОВ В АМИЛОИДНЫЕ ИЛИ АМИЛОИДПОДОБНЫЕ ОТЛОЖЕНИЯ, ИЛИ ИХ ПАТОЛОГИЧЕСКИЕ ПРЕДШЕСТВЕННИКИ, ОБОГАЩЕННЫЕ b-СКЛАДКАМИ
EP1646375A2 (en) * 2003-06-23 2006-04-19 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE GROOT NATALIA SANCHEZ.Prediction of "hot sports" of aggregation in disease-linked polypeptides.《BMC STRUCTURAL BIOLOGY》.2005,第5卷(第1期), *
PAWAR A P.Prediction of "Aggregation-prone"and "Aggregation-susceptible"Regions in Proteins Associated with Neurodegenerative Diseases.《JOURNAL OF MOLECULAR BIOLOGY》.2005,第350卷(第2期), *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108780098A (zh) * 2016-01-06 2018-11-09 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法
CN108780098B (zh) * 2016-01-06 2021-12-17 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法

Also Published As

Publication number Publication date
IL196551A (en) 2013-01-31
SG173405A1 (en) 2011-08-29
EA016884B1 (ru) 2012-08-30
KR20090047470A (ko) 2009-05-12
EP2047393A1 (en) 2009-04-15
CN101501694A (zh) 2009-08-05
US8290713B2 (en) 2012-10-16
JP2009545756A (ja) 2009-12-24
CA2657847A1 (en) 2008-02-07
WO2008015384A1 (en) 2008-02-07
HK1131239A1 (en) 2010-01-15
AU2007280282A1 (en) 2008-02-07
AU2007280282B2 (en) 2012-02-02
US20100160602A1 (en) 2010-06-24
IL196551A0 (en) 2009-11-18
WO2008015384A8 (en) 2008-05-15
EA200970180A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
CN101501694B (zh) 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法
Qiu et al. Artificial intelligence for drug discovery and development in Alzheimer’s disease
Louros et al. Structure-based machine-guided mapping of amyloid sequence space reveals uncharted sequence clusters with higher solubilities
Man et al. Effects of all-atom molecular mechanics force fields on amyloid peptide assembly: The case of aβ16–22 dimer
Teixeira et al. IDPConformerGenerator: a flexible software suite for sampling the conformational space of disordered protein states
Shell et al. A test on peptide stability of AMBER force fields with implicit solvation
Uversky et al. Multiparametric analysis of intrinsically disordered proteins: looking at intrinsic disorder through compound eyes
Charoenkwan et al. iAMY-SCM: Improved prediction and analysis of amyloid proteins using a scoring card method with propensity scores of dipeptides
Sommer et al. Structure-guided isoform identification for the human transcriptome
Pallarès et al. Advances in the prediction of protein aggregation propensity
Louros et al. Mapping the sequence specificity of heterotypic amyloid interactions enables the identification of aggregation modifiers
Orr et al. Uncovering the Binding and Specificity of β-Wrapins for Amyloid-β and α-Synuclein
Kunze et al. Molecular simulations reveal distinct energetic and kinetic binding properties of [18F] PI-2620 on tau filaments from 3R/4R and 4R Tauopathies
Fatafta et al. A brief history of amyloid aggregation simulations
Robinson et al. Are AMBER force fields and implicit solvation models additive? A folding study with a balanced peptide test set
Sanches et al. Examining the ensembles of amyloid-β monomer variants and their propensities to form fibers using an energy landscape visualization method
Linh et al. Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study
Pujols et al. A3D 2.0 update for the prediction and optimization of protein solubility
Huang et al. Unveiling medin folding and dimerization dynamics and conformations via atomistic discrete molecular dynamics simulations
Yuwen et al. Role of electrostatic interactions in binding of peptides and intrinsically disordered proteins to their folded targets: 2. The model of encounter complex involving the double mutant of the c-Crk N-SH3 domain and peptide Sos
Li et al. Simple and Effective Conformational Sampling Strategy for Intrinsically Disordered Proteins Using the UNRES Web Server
Tsiolaki et al. Mining databases for protein aggregation: a review
Zganec et al. Assembly of stefin B into polymorphic oligomers probed by discrete molecular dynamics
HK1131239B (en) Method for predicting protein aggregation and designing aggregation inhibitors
Do et al. Elucidation of the Aggregation Pathways of Helix–Turn–Helix Peptides: Stabilization at the Turn Region Is Critical for Fibril Formation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131239

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131239

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111130

Termination date: 20140724

EXPY Termination of patent right or utility model